Indian drugmaker Zydus Lifesciences (formerly Cadila Healthcare ) has received approval for its New Drug Application (NDA) from the Drug Controller General of India (DCGI) for Desidustat (branded as Oxemia), a first-of-its-kind oral treatment in India for anaemia associated with chronic kidney disease (CKD). Oxemia is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor.